Journal list menu
Export Citations
Download PDFs
ISSUE INFORMATION
LETTER TO THE JOURNAL
Open Access
oa
Cytotoxic and regulatory T cell interactions calculated from image mass cytometry predict immunochemotherapy response in triple-negative breast cancer
- Pages: 392-396
- First Published: 03 January 2025
Open Access
oa
Incidence of and survival with bone and soft tissue sarcoma: A nation-wide study over four decades
- Pages: 397-400
- First Published: 03 January 2025
Open Access
oa
Efficient 5-ALA-photodynamic therapy in nasopharyngeal carcinoma induces an immunoactivation mediated by tumoral extracellular vesicles and associated with immunogenic cell death
- Pages: 401-405
- First Published: 03 January 2025
Open Access
oa
Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3-dependent necroptotic inflammation
- Pages: 406-410
- First Published: 04 January 2025
ORIGINAL ARTICLE
Open Access
oa
A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study
- Pages: 411-421
- First Published: 04 January 2025
LETTER TO THE JOURNAL
Open Access
oa
Single-cell multi-omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK-positive lung cancer
- Pages: 422-427
- First Published: 04 January 2025
Open Access
oa
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd
- Pages: 428-432
- First Published: 06 January 2025
Open Access
oa
Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression-associated transcriptome changes and therapeutic vulnerabilities
- Pages: 433-437
- First Published: 07 January 2025
RESEARCH HIGHLIGHTS
Open Access
oa
Training the synergy between Bacillus Calmette-Guérin and immune checkpoint-blocking antibodies in bladder cancer
- Pages: 438-441
- First Published: 10 January 2025
ORIGINAL ARTICLE
Open Access
oa
Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial
- Pages: 442-455
- First Published: 10 January 2025
LETTER TO THE JOURNAL
Open Access
oa
To what extent is the association between obesity and colorectal cancer risk mediated by systemic inflammation?
- Pages: 456-459
- First Published: 10 January 2025
Open Access
oa
Targeting ferroptosis resistance resensitizes metastatic HR+HER2− breast cancer cells to palbociclib-hormone therapy
- Pages: 460-464
- First Published: 13 January 2025
Open Access
oa
Single-cell transcriptomics and epigenomics point to CD58-CD2 interaction in controlling primary melanoma growth and immunity
- Pages: 465-470
- First Published: 15 January 2025
Open Access
oa
Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives
- Pages: 471-475
- First Published: 16 January 2025
ORIGINAL ARTICLE
Open Access
oa
Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial
- Pages: 476-485
- First Published: 18 January 2025
LETTER TO THE JOURNAL
Open Access
oa
Inhibition of mTOR attenuates the initiation and progression of BRCA1-associated mammary tumors
- Pages: 486-490
- First Published: 18 January 2025